Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions — Stella

Home/Traumatic Brain Injury/

View on ClinicalTrials.gov

Recruiting

Back to Traumatic Brain Injury trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Tandu Hospital, Fourth Military Medical University, Xi'an, Shaanxi

Key details

Phase

Safety & dosing

Sponsor

Tang-Du Hospital

Collaborators

Qianxian People's Hospital, Weinan Central Hospital

Enrollment target

~100 participants

Started

November 2023

Primary completion

June 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years – 80 Years

Last updated April 2026